Evrysdi (risdiplam)
Information on this site is not intended as medical advice and should not be used as a substitute for consulting with a qualified doctor.
Evrysdi is an orally administered small molecule therapy that works by increasing the production of functional survival motor neuron (SMN) protein, which is deficient in patients with spinal muscular atrophy (SMA). By raising SMN protein levels in the central nervous system and peripheral tissues, Evrysdi helps slow disease progression, improve motor function, and support daily activities in patients living with SMA.1
In Bangladesh Evrysdi is approved for the following indications.1
Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA).
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Evrysdi is available as
0.75 mg / ml Oral Solution 1 Bottle
is the authorized importer and distributor for Roche pharmaceutical medicines in Bangladesh. To meet strict quality and compliance, Radiant maintains temperature controlled supply chain.
To ensure patient safety and quality, it is strongly recommended to verify that, each medicine comes with the Roche Hologram Sticker, DGDA approved DAR (Drug Administration Registration) Number imprinted on it. Neither Radiant nor Roche Bangladesh takes liability of any other sources of products.
:quality(90)/)
References
Evrysdi Product Information RO7034067 October 2023
Solutions
:quality(90)/)